A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Exclusion Criteria

• •Progression of systemic disease at Screening
• •Leptomeningeal disease
• •History of intolerance or hypersensitivity to study drug
• •Use of certain investigational therapies within 21 days prior to enrollment
• •Current anthracycline use
• •Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use
• •Active infection
• •Pregnant or lactating women
• •Significant history or risk of cardiac disease
• •Symptomatic intrinsic lung disease or lung involvement
• •History of other malignancy within the last 5 years